摘要
AIM:To determine the role of CD133 in cholangiocarcinoma progression. METHODS:CD133 protein expression was evaluated by immunohistochemistry in 34 cholangiocarcinoma specimens.In addition,proliferation,chemoresistance and invasive properties of CD133-enriched(CD133 + ) and CD133-depleted(CD133 )RMCCA1 cholangiocarcinoma cells were studied and compared. RESULTS:Strong CD133 expression was observed in 67.6%(23/34)of the cholangiocarcinoma specimens. Strong expression of CD133 was significantly associated with nodal metastasis(P=0.009)and positive surgical margin status(P=0.011).In the in vitro study, both the CD133 + and CD133 cells had similar proliferation abilities and resistance to chemotherapeutic drugs.However,the CD133 + cells had a higher invasive ability compared with CD133 cells. CONCLUSION:CD133+cells play an important role in the invasiveness of cholangiocarcinoma.Targeting of the CD133+cells may be a useful approach to improve treatment against cholangiocarcinoma.
AIM：To determine the role of CD133 in cholangiocarcinoma progression. METHODS：CD133 protein expression was evaluated by immunohistochemistry in 34 cholangiocarcinoma specimens.In addition,proliferation,chemoresistance and invasive properties of CD133-enriched（CD133 ＋ ） and CD133-depleted（CD133 ）RMCCA1 cholangiocarcinoma cells were studied and compared. RESULTS：Strong CD133 expression was observed in 67.6%（23/34）of the cholangiocarcinoma specimens. Strong expression of CD133 was significantly associated with nodal metastasis（P=0.009）and positive surgical margin status（P=0.011）.In the in vitro study, both the CD133 ＋ and CD133 cells had similar proliferation abilities and resistance to chemotherapeutic drugs.However,the CD133 ＋ cells had a higher invasive ability compared with CD133 cells. CONCLUSION：CD133＋cells play an important role in the invasiveness of cholangiocarcinoma.Targeting of the CD133＋cells may be a useful approach to improve treatment against cholangiocarcinoma.
基金
Supported by Rajavithi Hospital Project Grant and Thailand Research Fund(RSA52)
